JPS615787A - 昆虫細胞内でのポリペプチド類の産生 - Google Patents
昆虫細胞内でのポリペプチド類の産生Info
- Publication number
- JPS615787A JPS615787A JP60017702A JP1770285A JPS615787A JP S615787 A JPS615787 A JP S615787A JP 60017702 A JP60017702 A JP 60017702A JP 1770285 A JP1770285 A JP 1770285A JP S615787 A JPS615787 A JP S615787A
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- virus
- gene product
- vector
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000238631 Hexapoda Species 0.000 title claims description 51
- 238000004519 manufacturing process Methods 0.000 title claims description 14
- 229920001184 polypeptide Polymers 0.000 title claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 145
- 241000700605 Viruses Species 0.000 claims description 97
- 239000013612 plasmid Substances 0.000 claims description 61
- 239000013598 vector Substances 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 101710182846 Polyhedrin Proteins 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 30
- 241000701447 unidentified baculovirus Species 0.000 claims description 24
- 230000003612 virological effect Effects 0.000 claims description 24
- 238000003780 insertion Methods 0.000 claims description 9
- 230000037431 insertion Effects 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 3
- 108010067390 Viral Proteins Proteins 0.000 claims 6
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims 4
- 241001367049 Autographa Species 0.000 claims 2
- 241001203868 Autographa californica Species 0.000 claims 2
- 101100408464 Caenorhabditis elegans plc-1 gene Proteins 0.000 claims 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 66
- 210000004027 cell Anatomy 0.000 description 57
- 208000015181 infectious disease Diseases 0.000 description 51
- 239000000047 product Substances 0.000 description 20
- 108010005774 beta-Galactosidase Proteins 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 13
- 102000005936 beta-Galactosidase Human genes 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000009278 visceral effect Effects 0.000 description 11
- 230000004927 fusion Effects 0.000 description 10
- 210000001835 viscera Anatomy 0.000 description 10
- 230000002458 infectious effect Effects 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 101710172804 K protein Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241000701451 unidentified granulovirus Species 0.000 description 7
- 108020005202 Viral DNA Proteins 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000002917 insecticide Substances 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000575 pesticide Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108020004638 Circular DNA Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960005091 chloramphenicol Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010093031 Galactosidases Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000087 hemolymph Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 101150059280 jar gene Proteins 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 230000009279 non-visceral effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XNCSCQSQSGDGES-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]propyl-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(O)=O XNCSCQSQSGDGES-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 241000218642 Abies Species 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000908115 Bolivar Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000008100 Brassica rapa Species 0.000 description 1
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010001517 Galectin 3 Proteins 0.000 description 1
- 102100039558 Galectin-3 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000256259 Noctuidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000004920 integrated pest control Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001807 normal pulse voltammetry Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57545384A | 1984-01-31 | 1984-01-31 | |
| US575453 | 1984-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS615787A true JPS615787A (ja) | 1986-01-11 |
Family
ID=24300383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60017702A Pending JPS615787A (ja) | 1984-01-31 | 1985-01-31 | 昆虫細胞内でのポリペプチド類の産生 |
Country Status (9)
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01285198A (ja) * | 1988-05-12 | 1989-11-16 | Zenji Matsuura | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
| JPH0221955A (ja) * | 1988-07-07 | 1990-01-24 | Nippon Steel Corp | 流体噴射ノズル |
| JPH03500602A (ja) * | 1987-07-24 | 1991-02-14 | カイロン コーポレーション | 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地 |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879236A (en) * | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| JPS619288A (ja) * | 1984-06-21 | 1986-01-16 | Dai Ichi Seiyaku Co Ltd | ペプチド類の製法 |
| IL80529A0 (en) * | 1985-11-14 | 1987-02-27 | Daiichi Seiyaku Co | Method of producing peptides |
| KR950001993B1 (ko) * | 1985-12-18 | 1995-03-08 | 마이크로제네시스,인코포레이티드 | B형 간염 표면항원의 제조방법 |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US6150328A (en) | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
| GR871029B (en) | 1986-07-14 | 1987-11-02 | Genetics Inst | Novel osteoinductive factors |
| EP0260090A3 (en) * | 1986-09-08 | 1988-07-27 | David H.L. Bishop | Expression of hepatitis b viral antigens from recombinant baculovirus vectors |
| ZA876696B (en) * | 1986-09-09 | 1988-05-25 | Genetics Inst | Method for producing a heterologous protein in insect cells |
| US5071748A (en) * | 1986-09-09 | 1991-12-10 | Genetics Institute, Inc. | Mixed baculovirus compositions and uses thereof |
| US5041379A (en) * | 1987-03-16 | 1991-08-20 | American Biogenetic Science, Inc. | Heliothis expression systems |
| US5443964A (en) * | 1987-08-10 | 1995-08-22 | Duke University | Poxvirus insertion/expression vector |
| US5578468A (en) * | 1987-08-10 | 1996-11-26 | Duke University | Site-specific RNA cleavage |
| GB8810808D0 (en) * | 1988-05-06 | 1988-06-08 | Wellcome Found | Vectors |
| SE8802939D0 (sv) * | 1988-08-19 | 1988-08-19 | Kabigen Ab | A method for the production and isolation of a fusion protein in eukaryotic cells |
| US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| AU4647889A (en) * | 1988-11-18 | 1990-06-12 | Cetus Corporation | Insect signal peptide mediated secretion of recombinant proteins |
| US5244805A (en) * | 1989-05-17 | 1993-09-14 | University Of Georgia Research Foundation, Inc. | Baculovirus expression vectors |
| EP0612348B1 (en) | 1991-11-04 | 2003-04-23 | Genetics Institute, LLC | Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| ATE258984T1 (de) | 1993-05-12 | 2004-02-15 | Inst Genetics Llc | Bmp-11 zusammensetzungen |
| US6291206B1 (en) | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
| US6027919A (en) | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
| DE69434651T2 (de) | 1993-12-07 | 2007-03-08 | Genetics Institute, Inc., Cambridge | Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen |
| AU1377395A (en) | 1993-12-23 | 1995-07-10 | University Technologies International Inc. | Methods of expressing proteins in insect cells and methods of killing insects |
| US5629167A (en) | 1994-04-19 | 1997-05-13 | Biocine S.P.A. | Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| US6165748A (en) | 1997-07-11 | 2000-12-26 | Genetics Institute, Inc. | Frazzled nucleotide sequences and expression products |
| ATE505478T1 (de) | 1997-08-27 | 2011-04-15 | Novartis Vaccines & Diagnostic | Molekular-mimetika von meningokokkalen b epitopen |
| WO1999024578A2 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| WO1999036544A2 (en) | 1998-01-14 | 1999-07-22 | Chiron S.P.A. | Neisseria meningitidis antigens |
| GB9808932D0 (en) | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
| ES2537575T3 (es) | 1998-05-01 | 2015-06-09 | Novartis Ag | Antígenos y composiciones de neisseria meningitidis |
| WO2001031019A2 (en) | 1999-10-29 | 2001-05-03 | Chiron Spa | Neisserial antigenic peptides |
| JP2002527066A (ja) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | 転移性乳癌および結腸癌調節遺伝子 |
| ATE408695T1 (de) | 1998-12-16 | 2008-10-15 | Novartis Vaccines & Diagnostic | Menschliche cyclin-abhängige kinase (hpnqalre) |
| US6727224B1 (en) | 1999-02-01 | 2004-04-27 | Genetics Institute, Llc. | Methods and compositions for healing and repair of articular cartilage |
| DK1228217T3 (da) | 1999-04-30 | 2013-02-25 | Novartis Vaccines & Diagnostic | Konserverede neisseria-antigener |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| EP2308974A3 (en) | 1999-10-14 | 2011-08-10 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
| EP2286847A1 (en) | 1999-10-15 | 2011-02-23 | Genetics Institute, LLC | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| AU2001229367A1 (en) | 2000-01-10 | 2001-07-24 | Chiron Corporation | Genes differentially expressed in breast cancer |
| EP1897555B1 (en) | 2000-01-17 | 2014-07-16 | Novartis Vaccines and Diagnostics S.r.l. | Supplemented OMV vaccine against meningococcus |
| US6689599B1 (en) | 2000-10-20 | 2004-02-10 | Genetics Institute, Llc | Aggrecanase molecules |
| MX357775B (es) | 2000-10-27 | 2018-07-20 | J Craig Venter Inst Inc | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| WO2002081642A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene brcc-3 and diagnostic and therapeutic uses thereof |
| AU2002303261A1 (en) | 2001-04-06 | 2002-10-21 | Georgetown University | Gene brcc2 and diagnostic and therapeutic uses thereof |
| WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| ES2305246T3 (es) | 2001-06-01 | 2008-11-01 | Wyeth | Composiciones para la administracion sistemica de secuencias que codifican proteinas oseas morfogeneticas. |
| TWI267378B (en) | 2001-06-08 | 2006-12-01 | Wyeth Corp | Calcium phosphate delivery vehicles for osteoinductive proteins |
| AU2002319703A1 (en) | 2001-07-27 | 2003-02-17 | Wyeth | Aggrecanase molecules |
| CA2469620A1 (en) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
| CA2467383C (en) | 2001-12-19 | 2012-08-28 | The University Of Chicago | Rapidly maturing fluorescent proteins and methods for using the same |
| WO2003064622A2 (en) | 2002-01-31 | 2003-08-07 | Wyeth | Aggrecanase molecules |
| CA2475329A1 (en) | 2002-02-05 | 2003-08-14 | Katy E. Georgiadis | Truncated aggrecanase molecules |
| US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
| US7138512B2 (en) | 2002-04-10 | 2006-11-21 | Georgetown University | Gene SHINC-2 and diagnostic and therapeutic uses thereof |
| CA2485695A1 (en) | 2002-05-24 | 2003-12-04 | Fred W. Wagner | Method for universal enzymatic production of bioactive peptides |
| CA2485703A1 (en) | 2002-05-24 | 2003-12-04 | Fred W. Wagner | Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
| WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| AU2004272072B2 (en) | 2003-09-12 | 2010-07-08 | Etex Corporation | Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| PL1704234T3 (pl) | 2003-11-21 | 2012-06-29 | Nps Pharma Inc | Wytwarzanie glukagonopodobnego peptydu 2 i analogów |
| MXPA06008496A (es) | 2004-02-02 | 2007-01-30 | Ambrx Inc | Polipeptidos de interferon humano modificados y sus usos. |
| JP4792390B2 (ja) | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | 新規ガレクチン９改変体タンパク質及びその用途 |
| US7250298B2 (en) | 2004-04-07 | 2007-07-31 | The University Of Chicago | Monomeric red fluorescent proteins |
| NZ551335A (en) | 2004-06-18 | 2010-03-26 | Ambrx Inc | Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker |
| CA2569381A1 (en) | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| KR20070090023A (ko) | 2004-12-22 | 2007-09-04 | 암브룩스, 인코포레이티드 | 변형 인간 성장 호르몬 |
| EP1828224B1 (en) | 2004-12-22 | 2016-04-06 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
| CA2602175C (en) | 2005-03-21 | 2012-11-27 | Applera Corporation | Alpha ketoamide compounds as cysteine protease inhibitors |
| AU2006247591B2 (en) | 2005-05-12 | 2011-12-15 | Zymogenetics, Inc. | Compositions and methods for modulating immune responses |
| US7749704B2 (en) | 2005-11-01 | 2010-07-06 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the BLyS gene and use in diagnostic methods |
| CA2626522A1 (en) | 2005-11-16 | 2007-05-24 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
| EP2054431B1 (en) | 2006-06-09 | 2011-08-31 | Novartis AG | Conformers of bacterial adhesins |
| EP2615108B1 (en) | 2006-09-08 | 2016-10-26 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and thier uses |
| US7985783B2 (en) | 2006-09-21 | 2011-07-26 | The Regents Of The University Of California | Aldehyde tags, uses thereof in site-specific protein modification |
| KR20160121601A (ko) | 2007-03-30 | 2016-10-19 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| KR101662622B1 (ko) | 2007-10-04 | 2016-10-05 | 지모제넥틱스, 인코포레이티드 | Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법 |
| WO2009059305A2 (en) | 2007-11-01 | 2009-05-07 | The University Of Chicago | Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| EP2217265B1 (en) | 2007-11-20 | 2017-05-10 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| US8003325B2 (en) | 2007-11-30 | 2011-08-23 | Mayo Foundation For Medical Education And Research | Polymorphisms of the BLyS gene and use in diagnostic methods |
| EP2247743B1 (en) | 2008-02-08 | 2016-04-06 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| ES2963062T3 (es) | 2008-07-23 | 2024-03-25 | Ambrx Inc | Polipéptidos G-CSF bovinos modificados y sus usos |
| NZ592249A (en) | 2008-09-26 | 2013-03-28 | Ambrx Inc | Non-natural amino acid replication-dependent microorganisms and vaccines |
| KR101647164B1 (ko) | 2008-09-26 | 2016-08-09 | 암브룩스, 인코포레이티드 | 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도 |
| EP2292781A1 (en) | 2009-08-17 | 2011-03-09 | Genethon | Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions |
| EP2333074A1 (en) | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| PE20121799A1 (es) | 2009-12-21 | 2013-01-02 | Ambrx Inc | Polipeptidos de somatotropina porcina modificados y sus usos |
| JP2013515080A (ja) | 2009-12-21 | 2013-05-02 | アンブルックス，インコーポレイテッド | 修飾されているウシのソマトトロピンポリペプチドおよびそれらの使用 |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| RS59193B1 (sr) | 2010-08-17 | 2019-10-31 | Ambrx Inc | Modifikovani polipeptidi relaksina i njihova primena |
| AR083006A1 (es) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
| US10480010B2 (en) | 2011-07-27 | 2019-11-19 | Genethon | Baculovirus expression systems |
| KR102484396B1 (ko) | 2013-09-12 | 2023-01-04 | 바이오마린 파머수티컬 인크. | 아데노-관련된 바이러스 인자 viii 벡터 |
| EP3209316A2 (en) | 2014-10-24 | 2017-08-30 | Bristol-Myers Squibb Company | Modified fgf-21 polypeptides and uses thereof |
| KR102805910B1 (ko) | 2015-09-24 | 2025-05-13 | 바이오마린 파머수티컬 인크. | 아데노-관련 바이러스 인자 viii 벡터, 연합된 바이러스 입자 및 이를 포함하는 치료학적 제형 |
| RU2761264C2 (ru) | 2015-11-12 | 2021-12-06 | Рисерч Инститьют Эт Нэшнуайд Чилдрен'С Хоспитал | Способы лечения мышечной дистрофии |
| SG11201811603WA (en) | 2016-07-26 | 2019-02-27 | Biomarin Pharm Inc | Novel adeno-associated virus capsid proteins |
| SG10201912034UA (en) | 2017-02-08 | 2020-02-27 | Bristol Myers Squibb Co | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
| WO2019067982A2 (en) | 2017-09-29 | 2019-04-04 | Massachusetts Eye And Ear Infirmary | PRODUCTION OF ADENO-ASSOCIATED VIRUSES IN INSECT CELLS |
| WO2019152474A1 (en) | 2018-01-31 | 2019-08-08 | Research Institute At Nationwide Children's Hospital | Gene therapy for limb-girdle muscular dystrophy type 2c |
| CN113164762A (zh) | 2018-05-09 | 2021-07-23 | 生物马林药物股份有限公司 | 苯丙酮尿症的治疗方法 |
| TW202016298A (zh) | 2018-05-14 | 2020-05-01 | 美商拜奧馬林製藥公司 | Aav 載體於幼年受試者中之穩定表現 |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| TWI854984B (zh) | 2018-06-29 | 2024-09-11 | 美國全美兒童醫院之研究學會 | 用於治療肢帶型肌營養不良症2a之重組腺相關病毒產品與方法 |
| AU2020229340A1 (en) | 2019-02-26 | 2021-09-16 | Research Institute At Nationwide Children's Hospital | Adeno-associated virus vector delivery of B-sarcoglycan and the treatment of muscular dystrophy |
| TW202104592A (zh) | 2019-05-14 | 2021-02-01 | 美商拜奧馬林製藥公司 | 重複投予基因療法載體之方法 |
| MX2022002132A (es) | 2019-08-21 | 2022-05-18 | Res Inst Nationwide Childrens Hospital | Administracion de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular. |
| CA3153782A1 (en) | 2019-09-27 | 2022-03-08 | Biomarin Pharmaceutical Inc. | Characterization of gene therapy viral particles using size exclusion chromatography and multi-angle light scattering technologies |
| US20230340078A1 (en) | 2019-11-14 | 2023-10-26 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with liver-specific gene therapy vectors |
| US20230075854A1 (en) | 2020-02-10 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Virus-free cell cultures |
| WO2021183895A1 (en) | 2020-03-13 | 2021-09-16 | Biomarin Pharmaceutical Inc. | Treatment of fabry disease with aav gene therapy vectors |
| AR122409A1 (es) | 2020-04-03 | 2022-09-07 | Biomarin Pharm Inc | Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas |
| WO2021236908A2 (en) | 2020-05-20 | 2021-11-25 | Biomarin Pharmaceutical Inc. | Use of regulatory proteins for the production of adeno-associated virus |
| CA3196778A1 (en) | 2020-11-02 | 2022-05-05 | Biomarin Pharmaceutical, Inc. | Process for enriching adeno-associated virus |
| US20240408240A1 (en) | 2021-10-01 | 2024-12-12 | Biomarin Pharmaceutical Inc. | Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations |
| US12285497B2 (en) | 2021-10-15 | 2025-04-29 | Research Institute At Nationwide Children's Hospital | Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy |
| WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
| EP4590839A1 (en) | 2022-09-22 | 2025-07-30 | Dinaqor AG | Treatment of cardiomyopathy with aav gene therapy vectors |
| TW202444398A (zh) | 2023-01-09 | 2024-11-16 | 美商拜奧馬林製藥公司 | 表觀遺傳修飾劑改善aav基因療法之耐久性 |
| WO2024238591A2 (en) | 2023-05-15 | 2024-11-21 | Biomarin Pharmaceutical Inc. | Methods of treating anti-aav seropositive hemophilia patients |
-
1984
- 1984-10-31 ZA ZA848495A patent/ZA848495B/xx unknown
- 1984-10-31 DK DK518384A patent/DK518384A/da not_active Application Discontinuation
- 1984-11-19 ES ES537766A patent/ES8604308A1/es not_active Expired
- 1984-12-26 IL IL73942A patent/IL73942A0/xx unknown
-
1985
- 1985-01-30 KR KR1019850000554A patent/KR850005499A/ko not_active Withdrawn
- 1985-01-30 GR GR850265A patent/GR850265B/el unknown
- 1985-01-31 JP JP60017702A patent/JPS615787A/ja active Pending
- 1985-01-31 AU AU38242/85A patent/AU3824285A/en not_active Abandoned
- 1985-01-31 EP EP85101009A patent/EP0155476A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500602A (ja) * | 1987-07-24 | 1991-02-14 | カイロン コーポレーション | 昆虫細胞の増殖およびそれによる生産物の発現のための無血清培地 |
| JPH01285198A (ja) * | 1988-05-12 | 1989-11-16 | Zenji Matsuura | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
| JPH0221955A (ja) * | 1988-07-07 | 1990-01-24 | Nippon Steel Corp | 流体噴射ノズル |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0155476A1 (en) | 1985-09-25 |
| ES8604308A1 (es) | 1986-01-16 |
| IL73942A0 (en) | 1985-03-31 |
| DK518384A (da) | 1985-07-01 |
| ZA848495B (en) | 1985-09-25 |
| GR850265B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1985-05-27 |
| AU3824285A (en) | 1985-08-08 |
| ES537766A0 (es) | 1986-01-16 |
| DK518384D0 (da) | 1984-10-31 |
| KR850005499A (ko) | 1985-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS615787A (ja) | 昆虫細胞内でのポリペプチド類の産生 | |
| US5753220A (en) | Cysteine protease gene defective baculovirus, process for its production, and process for the production of economic protein by using the same | |
| US5348886A (en) | Method of producing recombinant eukaryotic viruses in bacteria | |
| Gross et al. | Orgyia pseudotsugata baculovirus p10 and polyhedron envelope protein genes: analysis of their relative expression levels and role in polyhedron structure | |
| JP5986381B2 (ja) | ベクター | |
| US10513542B2 (en) | Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof | |
| JP2000300254A (ja) | 寄生体由来抵抗性 | |
| Yang et al. | Improving baculovirus infectivity by efficiently embedding enhancing factors into occlusion bodies | |
| JP2011519263A (ja) | レシピエント宿主細胞におけるゲノム組込み方法 | |
| EP0397485A1 (en) | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells | |
| CN102031263B (zh) | 应用家蚕生物反应器制备人DNA聚合酶δ的方法 | |
| Noad et al. | Multigene expression of protein complexes by iterative modification of genomic Bacmid DNA | |
| CN101372684A (zh) | 一种简便高效构建重组杆状病毒的方法 | |
| Xiang et al. | The Bombyx mori nucleopolyhedrovirus (BmNPV) ODV-E56 envelope protein is also a per os infectivity factor | |
| Byrd et al. | Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus | |
| JP2693948B2 (ja) | 侵入性微生物 | |
| JPS62503074A (ja) | 不安定な遺伝性レプリコンの安定化方法 | |
| MXPA04008753A (es) | Baculovirus disenados y su uso. | |
| CN102286534A (zh) | 表达多外源基因的昆虫生物反应器及其构建方法和应用 | |
| Atkinson et al. | Baculoviruses as vectors for foreign gene expression in insect cells | |
| EP0975787A1 (en) | Entomopoxvirus-based gene delivery vector for vertebrates | |
| NL8800198A (nl) | Baculovirus voor de bestrijding van insekten. | |
| Sun et al. | Production of recombinant Bombyx mori nucleopolyhedrovirus in silkworm by intrahaemocoelic injection with invasive diaminopimelate auxotrophic Escherichia coli containing BmNPV–Bacmid | |
| Hansen et al. | BiZyme: a novel fusion protein-mediating selection of vaccinia virus recombinants by fluorescence and antibiotic resistance | |
| Peng et al. | Function and Application Analysis of Ac132 Protein in Autographa californica Multiple Nucleopolyhedrovirus |